OncUpdates

1.7K posts

OncUpdates banner
OncUpdates

OncUpdates

@OncUpdates

Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice

Worldwide Katılım Kasım 2024
728 Takip Edilen904 Takipçiler
OncUpdates retweetledi
OncUpdates
OncUpdates@OncUpdates·
Best of luck to all the upcoming #HemOnc #Fellowship #Match applicants! @sawyer_bawek provides an update from the @ASCO Fellowship Application Essentials session at @ASCOTECAG 🔗Full link👇 #MedTwitter #OncTwitter @HemOncFellows @jamecancerdoc #MedX @JCOOP_ASCO @CleClinicMD
Sawyer Bawek, DO@sawyer_bawek

💥#Fellowship Application Essentials: Program Director Tips from #ASCO26 Trainee & Early Career Lounge Panel! ⭐️Key pearls for #HemOnc applicants! #ASCOConnection #ASCO @ASCO #OncTwitter #MedTwitter #MedEd @ASCOTECAG @hemeoncfellow @HemOncFellows connection.asco.org/do/fellowship-…

English
0
2
4
1.1K
OncUpdates retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
#ESMO26 titles released! We have two meta-analyses addressing dilemmas we frequently encounter in clinical practice: 🔹 In BRAF V600E-mutant NSCLC, should first-line treatment be BRAF/MEK inhibition or an IO-based approach? — with @OncBrothers 💫 🔹 In the neoadjuvant treatment of HER2-positive breast cancer, does adding carboplatin to dual anti-HER2 therapy provide additional benefit? Results at #ESMO26 😊
Yakup Ergün tweet media
ESMO - Eur. Oncology@myESMO

📣 #ESMO26: The place where oncology leaders choose to share their ground-breaking studies. More than 10% increase in abstract submissions compared to 2025. ⏰ Early registration deadline: 22 July 2026 🔗 ow.ly/TyBU50ZgQAm #esmomeetings

English
2
8
60
9.5K
OncUpdates retweetledi
Vincent Rajkumar
Vincent Rajkumar@VincentRK·
This trial shows more is not better. And this is something we have seen in myeloma before. With low dose dex compared to high dose dex. With once weekly bortezomib compared to twice weekly. And more recently with immunotherapy this is even more important. This is another lesson from this trial. @RahulBanerjeeMD @GKaurMD @NorthTxMSG @MyelomaTeacher @JanakiramMurali
English
1
9
38
2.9K
OncUpdates retweetledi
Oncology Brothers
Oncology Brothers@OncBrothers·
3 studies we touched on during our leukemia highlights from @EHA_Hematology #EHA2026 conference with @EuniceWangMD 1. OPTI-AML: 14d vs. 28d Ven (with Aza) 2. KOMET-007: Ziftomenib + 7+3 3. SENTRY: Selinexor + Ruxolitinib #leusm #HemeTwitter #MedX @OncUpdates
Oncology Brothers tweet media
Oncology Brothers@OncBrothers

Leukemia Highlights from #EHA2026 w/ @EuniceWangMD ⭐️ OPTI-AML ⭐️ KOMET-007 ⭐️ SENTRY Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ oncbrothers.com/leukemia-eha20… #HemeTwitter @OncUpdates #OncTwitter #leusm @RoswellPark @EHA_Hematology

English
1
9
17
3.7K
OncUpdates retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
Results from HER2CLIMB-04 show that combining T-DXd with tucatinib does not lead to higher efficacy than T-DXd monotherapy. Follows the disappointing results of HER2CLIMB-02 (T-DM1 + tuc). Tucatinib stabilizes HER2 on the membrane: bad partner for ADCs? clinical-breast-cancer.com/article/S1526-…
Paolo Tarantino tweet media
English
2
25
65
14.7K

Keşfet

@OncBrothers @NVijayvergiaMD @ASCO @sawyer_bawek @ASCOTECAG @HemOncFellows @jamecancerdoc @JCOOP_ASCO